Drugs Made In America Acquisition II (NASDAQ:DMII) Trading 0.1% Higher – Time to Buy?

Drugs Made In America Acquisition II Corp. (NASDAQ:DMII)’s share price rose 0.1% during trading on Friday . The company traded as high as $9.98 and last traded at $9.97. Approximately 73,659 shares were traded during mid-day trading, a decline of 41% from the average daily volume of 123,897 shares. The stock had previously closed at $9.96.

Analyst Ratings Changes

Separately, Weiss Ratings began coverage on Drugs Made In America Acquisition II in a report on Monday, March 2nd. They set a “sell (e)” rating on the stock. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Drugs Made In America Acquisition II has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Stock Performance

Hedge Funds Weigh In On Drugs Made In America Acquisition II

A number of institutional investors and hedge funds have recently modified their holdings of DMII. Geode Capital Management LLC purchased a new position in shares of Drugs Made In America Acquisition II in the 4th quarter worth $265,000. Virtu Financial LLC purchased a new stake in Drugs Made In America Acquisition II during the fourth quarter valued at $317,000. ABC Arbitrage SA bought a new position in Drugs Made In America Acquisition II in the fourth quarter valued at about $396,000. Deltec Asset Management LLC purchased a new position in Drugs Made In America Acquisition II in the fourth quarter worth about $495,000. Finally, Royal Bank of Canada bought a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter valued at about $655,000.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.